Singapore markets close in 4 hours 55 minutes

Vera Therapeutics, Inc. (VERA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
37.97-1.79 (-4.50%)
At close: 04:00PM EDT
38.21 +0.24 (+0.63%)
After hours: 05:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close39.76
Open39.78
Bid37.94 x 200
Ask38.05 x 100
Day's range37.78 - 39.86
52-week range7.10 - 50.78
Volume575,999
Avg. volume958,816
Market cap2.175B
Beta (5Y monthly)1.11
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

    Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2 trial expected in Q4 2024Pivotal Phase 3 ORIGIN 3 trial estimated to complete enrollment for primary endpoint in Q3 2024; topline data expected in 1H 2025Completed $287.5 million financing, further strengthening the Company’s balance sheet BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Vera The

  • GlobeNewswire

    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A common stock and restricted stock units (RSUs) for 7,500 shares of Class A common stock to three new employees under Vera’s 2024 Inducement Plan (the Inducement Plan). Vera also announced that on May 6, 2024, the

  • GlobeNewswire

    Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

    72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced two presentations of data from the Phase 2b ORIGIN clinical trial o